Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) continues
to strengthen its vertically integrated psychedelic medicine ecosystem via the
acceleration of its ketamine topicals prescription fulfillment capabilities.
The company today announced the addition of central fill and compounding
infrastructure for its proprietary ketamine formulations via a location at one
of Canada’s leading retail pharmacy chains (the “Pharmacy”), as well as the
dispensing of its products throughout the Pharmacy’s network. “With this
arrangement, Champignon boasts complete vertical integration with respect to
our rapid onset ketamine treatments and therapies,” Champignon CEO Gareth
Birdsall stated in the news release. “From novel formulations to product
development at a purpose-built GMP and DIN licensed pharmaceutical facility,
and now automated prescription fulfillment and on-site compounding
infrastructure, we have managed to capture the entire product lifecycle.”
In addition, Champignon announced the closing of its
acquisition of AltMed Capital Corp., subject to the submission of the necessary
filings to the BC Corporate Registry and including any other necessary
regulatory approvals. AltMed is a Canadian ketamine clinic operator,
psychedelic medicine IP aggregator and novel drug discoverer with a suite of
assets that will accelerate Champignon’s multipronged business strategy. This
will enable the company to reach the consumer directly through rapid-onset
medical treatments, with an anticipated rollout of already identified new
clinical entities (“NCEs”) to be opened across the United States and Canada.
To view the full press release, visit http://ibn.fm/zTUCj
About Champignon Brands Inc.
Champignon Brands Inc. is a research-driven company
specializing in the formulation of a suite of medicinal mushrooms health
products, as well as novel ketamine, anaesthetics and adaptogenic delivery
platforms for the nutritional, wellness and alternative medicine industries.
Via its vertically integrated alternative medicine product range, Champignon is
pursuing the development and commercialization of rapid onset treatments
capable of improving health outcomes, such as depression and post-traumatic
stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under
a collaborative research agreement with the University of Miami’s Miller School
of Medicine, the Company is conducting pre-clinical studies and eventual human
clinical trials, with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with PTSD or
stand-alone PTSD. Champignon continues to be inspired by sustainability, as its
medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For
more information, visit the company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment